logo

BETHKIS® (Tobramycin Inhalation Solution)

Concentrated Formulation for Efficient Nebulization

Concentrated Formulation for Efficient Nebulization

300 mg of Tobramycin in Less Volume1,2

BETHKIS® (Tobramycin Inhalation Solution) is a concentrated solution delivering 300 mg of nebulized tobramycin in only 4 mL.1 The solution offers osmolarity similar to that of airway surface liquid in patients with cystic fibrosis.3,4

Efficient Nebulization
  • Approximate 15-minute administration time1
Benefits Demonstrated in Pivotal Clinical Studies vs Placebo
  • Proven efficacy
    • Significant improvements in lung function, decrease in density of Pseudomonas aeruginosa in sputum, and reduced patient burden1,3-5
  • Favorable safety profile
    • Adverse event rates similar to placebo1
    • Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia
  • Local tolerability
    • Generally well tolerated with a low incidence of voice alteration and bronchospasm1,6
    • Incidence of wheezing similar to placebo1,6
  • High compliance
    • Mean treatment compliance ≥98% across clinical trials5,6
Indication

BETHKIS® (Tobramycin Inhalation Solution) is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia.

Important Safety Information

BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside.

Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and wheezing should be treated as medically appropriate.

Caution should be exercised when prescribing BETHKIS to patients with known or suspected auditory, vestibular, renal, or neuromuscular dysfunction. Audiograms, serum concentration, and renal function should be monitored as appropriate.

Avoid concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic or ototoxic potential.

BETHKIS should not be administered concurrently with ethacrynic acid, furosemide, urea, or mannitol.

Aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.

Fetal harm can occur when aminoglycosides are administered to a pregnant woman. Apprise women of the potential hazard to the fetus.

Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

Please see full prescribing information.

 

This Web site is intended for United States residents only.


REGISTER NOW:
Get the latest information about BETHKIS® (Tobramyin Inhalation Solution) as it becomes available.

First Name*

Last Name*

Email*


By submitting your e-mail address, you are giving Cornerstone Therapeutics permission to send you information and updates on BETHKIS or other Cornerstone products in the future. Cornerstone Therapeutics will not sell or share any of your information with third parties.